Evidence map›Paper›PMID 42825383›Full record

ArticleJournal of peptide science : an official publication of the European Peptide Society2026

Design, Synthesis and Biophysical Characterisation of CPP-PNA Conjugates for Targeting Oncogenic microRNA-221.

Martina Rotondo, Françoise Illien, Fabienne Burlina, Barbara Biondi

Abstract read
In one paragraph

Article in Journal of peptide science : an official publication of the European Peptide Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Design, Synthesis and Biophysical Characterisation of CPP-PNA Conjugates for Targeting Oncogenic microRNA-221.Journal of peptide science : an official publication of the European Peptide Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Martina RotondoUniversity of Naples Federico II, Naples, Italy.
Françoise IllienSorbonne Université, École Normale Supérieure, Université PSL, CNRS, Chimie Physique et Chimie du Vivant, CPCV, Paris, France.ORCID https://orcid.org/0000-0003-3414-8452
Fabienne BurlinaSorbonne Université, École Normale Supérieure, Université PSL, CNRS, Chimie Physique et Chimie du Vivant, CPCV, Paris, France.ORCID https://orcid.org/0000-0002-6042-680X
Barbara BiondiPadova Unit, Institute of Biomolecular Chemistry of CNR, Padova, Italy.ORCID https://orcid.org/0000-0003-2393-7333

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptide nucleic acids (PNAs) are a promising platform targeting disease-associated microRNAs due to their high binding affinity, excellent sequence specificity and resistance to enzymatic degradation. However, their therapeutic application is often limited by inefficient cellular uptake. In this study, we present the design, synthesis and physicochemical characterisation of cell-penetrating peptide (CPP)-PNA conjugates that target the oncogenic microRNA miRNA-221-5p, as well as their preliminary biological evaluation. Anti-miRNA-221-5p PNAs functionalised for conjugation with CPPs via Cu(I)-catalysed azide-alkyne cycloaddition (CuAAC) or disulfide-mediated coupling were synthesised using solid-phase peptide synthesis. Circular dichroism and UV-melting analyses confirmed the formation of a stable, sequence-specific PNA-RNA heteroduplex with miRNA-221-5p. This demonstrated strong hybridisation and high thermodynamic stability compared to scrambled control sequences. Cell proliferation assays indicated modest but reproducible antiproliferative effects for the CPP-PNA conjugates co-incubated with chloroquine, with no evidence of acute cytotoxicity. These findings emphasise the potential of CPP-PNA systems for the intracellular delivery of antisense agents and highlight the importance of the linker nature in determining their biological performance.

Indexed as

Cell-Penetrating PeptidesDrug DesignMicroRNAsPeptide Nucleic AcidsCell ProliferationHumansCell-Penetrating PeptidesMicroRNAsMIR221, humanPeptide Nucleic Acidsantisense therapycell‐penetrating peptides (CPPs)click chemistrydisulfide bridgemiRNA‐221peptide nucleic acids (PNAs)SPPS

Identifiers

PMID42825383
PMCPMC13631804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.